Navigation Links
Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
Date:4/17/2013

ase, acute limb ischemia, and blood transfusions, as well as the timing of activities related to those plans, and prospects for MST-188's clinical, regulatory and commercial success.  Among the factors that could cause or contribute to material differences between the Company's actual results and expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future nonclinical and clinical studies despite positive results in nonclinical testing and prior clinical studies; the potential for significant delays in the development of MST-188, including due to lack of funding, delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, completing necessary manufacturing process development activities, and being subject to a "clinical hold," or suspension or termination of a clinical study, including due to patient safety concerns; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of planned phase 2 clinical studies of MST-188 in any particular indication in which the Company determines to develop MST-188, including acute limb ischemia, which likely would increase the total time and cost of development in the indication; the risk that clinical studies of MST-188 are not successfully executed and/or do not successfully demonstrate its safety or efficacy; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the risk that even if clinical studies of MST-188 in one indication or jurisdiction are successful,
'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
2. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
3. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
4. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
5. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
6. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
7. Adenosine Therapeutics Engages Needham & Company to Explore Strategic Options for Phase III Cardiac Stress Agent
8. Halozyme Therapeutics Names Matt Posard to Board of Directors
9. Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
10. Cell Therapeutics Secures $15 Million Loan Financing Agreement
11. United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "12th Annual Report and ... report to their offering. The 2015 ... Capacity and Production is the most recent study ... and projected future capacity and production. The report ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Quetiapine Market Investigation Report 2010-2019 2
... COMBINATION WITH DIURETIC ACCEPTED FOR REVIEW BY,FDA- , ... 2007 -,Speedel (SWX: SPPN) today welcomed the significant ... by investigators at the 22nd Annual Scientific Meeting,and ... in,Chicago, IL, USA. These results confirm the favourable ...
... inflammation in models of,arthritis and Salmonella infection, ... -, WASHINGTON, May 21, 2007 /PRNewswire/ -- ... from two studies,that demonstrate the anti-inflammatory activity ... origin, Bifantis(R),(Bifidobacterium infantis 35624), in models of ...
Cached Medicine Technology:New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 2New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 3New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 4New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 5New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 7New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 8New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 9New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 10New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 11New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits 2New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits 3
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... and InHealth Media. Nutritional Products International and InHealth media is a global sales ... , “We are extremely pleased to continue our business relationship with Mr. Reid ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... devices for the treatment of prostate cancer, has announced the roll-out of its ... the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed Consent for ... 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic informed ... , Clinical trial sites can now use audio, video and interactivity to ...
(Date:8/29/2015)... ... August 29, 2015 , ... It ... and protection against dribbled urine and sweat. "In order to prevent these problems, ... The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Leicester and the University of Ferrara in Italy have collaborated ... cancer pain without causing many of the side effects of ... 90% of cancer patients experience pain in the final year ... the use of drugs like morphine produces side effects such ...
... appendicitis are often diffuse and it can be difficult to ... disease. It may be possible to predict the severity from ... on an individual basis. This is the conclusion of a ... know what causes appendicitis. There is evidence that the cause ...
... didn,t accurately diagnose elderly Asians, study found , MONDAY, ... year by the American Diabetes Association as an effective ... of Singapore suggests that the hemoglobin A1c blood test ... , The American Diabetes Association,s current recommendation is that ...
... ... well as the degree programs, you don,t need to look too far. A comprehensive guide ... useful awaits you at EducationCenters.com. A stop shop for all your education needs, this site ... , ...
... Reza ... as Exclusive Distributor/Manufacturer for Saudi Arabia and the Middle East, , ... Newark, NJ (PRWEB) June 21, 2010 -- BioNeutral Group ... Chief Scientist, Dr. Andy Kielbania, will assist with a similar role in Steri – 7, ...
... ... Enterprise Mobile Management drives down support costs, improves performance and service quality of mobility ... has made available a complimentary copy of the report in the link below. ... (PRWEB) June 21, ...
Cached Medicine News:Health News:New drugs to relieve cancer pain 2Health News:New possibility to determine the severity of appendicitis 2Health News:Age, Race May Affect Type 2 Diabetes Screening Results 2Health News:The Epicenter of Education Information is Not Too Far Away 2Health News:BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role 2Health News:BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role 3Health News:BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role 4Health News:Industry Benchmark Report Finds Full Mobile Lifecycle Management and ITSM Critical to Enterprise Mobile Management 2Health News:Industry Benchmark Report Finds Full Mobile Lifecycle Management and ITSM Critical to Enterprise Mobile Management 3Health News:Industry Benchmark Report Finds Full Mobile Lifecycle Management and ITSM Critical to Enterprise Mobile Management 4
... The Videoscopes provide superior image ... connecting to the camera head with ... density ensures more light at the ... provide optimum image clarity and reliability.,The ...
... Passport II delivery device is the second ... C11UB. Its simple-to-use syringe technology allows one-handed ... small incision. The blue colored plunger allows ... protect the haptics during insertion. The modified ...
... for long-term transtelephonic monitoring. Simple to use, ... in order to record all pre and post ... button, the patient sends the recorded ECG over ... for immediate diagnosis. Use of Heart 2005A is ...
... IMPACs comprehensive information system designed specifically ... integrate and streamline their diagnostic, management, ... intuitive software solution. Thousands of laboratory ... have proven PowerPaths unique "case-centric model ...
Medicine Products: